天域生物: 2025年第三次临时股东大会会议资料

Core Viewpoint - Tianyu Biotechnology Co., Ltd. is convening its third extraordinary general meeting of shareholders in 2025 to discuss various proposals, including a plan for issuing A-shares to specific investors, aimed at enhancing the company's capital structure and supporting its operational needs [1][2][10]. Group 1: Meeting Proposals - Proposal 1: The company meets the conditions for issuing A-shares to specific investors, having conducted a thorough self-assessment against regulatory requirements [10]. - Proposal 2: The plan for the 2025 issuance of A-shares to specific investors is outlined, with the issuance to be conducted at an appropriate time after regulatory approvals [11][12]. - Proposal 3: A detailed analysis report on the 2025 A-share issuance plan has been prepared and is available for review [19][20]. - Proposal 4: A feasibility analysis report on the use of funds raised from the A-share issuance has been compiled [21]. - Proposal 5: A special report on the use of previously raised funds has been prepared and audited [22]. - Proposal 6: The company will sign a conditional share subscription agreement with a related party, which is compliant with regulatory standards [23]. - Proposal 7: The impact of the A-share issuance on immediate returns and measures to mitigate any dilution of returns have been analyzed [25]. - Proposal 8: A three-year shareholder return plan (2025-2027) has been developed to enhance transparency in profit distribution [26]. - Proposal 9: The board seeks authorization to manage all matters related to the A-share issuance, including adjustments based on market conditions and regulatory requirements [30][32].